Chapter 52: Renal and Urinary Medications
Loading audio…
ⓘ This audio and summary are simplified educational interpretations and are not a substitute for the original text.
Urinary tract antiseptics including fosfomycin, methenamine, and nitrofurantoin serve as first-line treatments for uncomplicated urinary tract infections, requiring careful attention to contraindications in patients with renal impairment and awareness of urine pH requirements for optimal efficacy. Fluoroquinolone antibiotics such as ciprofloxacin and levofloxacin provide broad-spectrum coverage for more complex infections but necessitate monitoring for central nervous system toxicity, tendon rupture risk, and adequate hydration to prevent crystalluria complications. Sulfonamide therapy, particularly trimethoprim-sulfamethoxazole, requires vigilance for severe hypersensitivity reactions including Stevens-Johnson syndrome, hematologic abnormalities, and significant drug-drug interactions that can potentiate warfarin and hypoglycemic agents. The chapter addresses symptom management through urinary tract analgesics like phenazopyridine and anticholinergic agents such as oxybutynin and tolterodine for overactive bladder conditions, balanced against contraindications in patients with angle-closure glaucoma. Cholinergic medications like bethanechol address urinary retention in neurogenic bladder, with clear delineation of overdose signs and atropine reversal protocols. A substantial portion focuses on immunosuppressant medications used in kidney transplant rejection prevention, including cyclosporine with its nephrotoxicity and grapefruit juice interactions, tacrolimus with neurotoxicity and hyperglycemia risks, and mycophenolate with bone marrow suppression concerns. The chapter concludes with hematopoietic growth factors including epoetin alfa for chronic kidney disease-related anemia and filgrastim for neutropenia management, requiring baseline and periodic laboratory monitoring. Throughout, the content emphasizes drug compatibility, administration timing, patient education strategies, and nursing assessment parameters necessary for optimal therapeutic outcomes and adverse event prevention.